

# Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to [info@aihw.gov.au](mailto:info@aihw.gov.au).

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at [meteor@aihw.gov.au](mailto:meteor@aihw.gov.au).

# Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N

## Identifying and definitional attributes

<b>Metadata item type:</b>	Data Element
<b>Short name:</b>	Primary site of cancer (ICD-O-3 code)
<b>METEOR identifier:</b>	396090
<b>Registration status:</b>	<a href="#">Health</a> , Standard 07/12/2011
<b>Definition:</b>	The site in which the tumour originated in a person with cancer, as opposed to the secondary or metastatic sites, as represented by a code.
<b>Data Element Concept:</b>	<a href="#">Person with cancer—primary site of cancer</a>
<b>Value Domain:</b>	<a href="#">Topography code (ICD-O-3) ANN.N</a>

## Value domain attributes

## Representational attributes

<b>Classification scheme:</b>	<a href="#">International Classification of Diseases for Oncology 3rd edition</a>
<b>Representation class:</b>	Code
<b>Data type:</b>	String
<b>Format:</b>	ANN.N
<b>Maximum character length:</b>	5

## Collection and usage attributes

<b>Guide for use:</b>	Record all four alphanumeric characters of the topography code. The number after the decimal point represents the subsite or subcategory.
-----------------------	---

## Data element attributes

## Collection and usage attributes

<b>Guide for use:</b>	<p>Record the primary site of cancer, if known, for patients who have been diagnosed with cancer. When the primary site is unknown, record C80.9.</p> <p>The primary site of the tumour is the site of origin, as opposed to the secondary or metastatic site.</p> <p>Record all four alphanumeric characters of the topography code. The number after the decimal point represents the subsite or subcategory.</p> <p>Refer to the coding guidelines for topography in ICD-O-3, pp 23-26.</p> <p>Refer to the coding guidelines for multiple tumours in ICD-O-3, pp 35-37.</p> <p>If the patient is diagnosed with more than one primary tumour, record the site of each primary separately.</p> <p>If the primary site differs on multiple pathology or other notification reports for the same tumour, use the most specific value. For example, one report may state the breast (C50.9) is the site of the primary while another report records the lower-inner quadrant of the breast (C50.3) as the primary site; record C50.3 here as the primary site.</p>
-----------------------	--

**Collection methods:** This information should be obtained from the patient's medical record.

**Comments:** The information is collected so that tumours can be classified into clinically relevant groups based on their primary site and histological type. This provides a basis for staging and the determination of treatment options. The primary site of the cancer also affects the course of the disease and prognosis.

## Source and reference attributes

**Submitting organisation:** Cancer Australia

**Origin:** World Health Organization

**Reference documents:** Fritz A et al. 2000. International Classification of Diseases for Oncology (ICD-O), 3rd edition. Geneva: World Health Organization

## Relational attributes

**Related metadata references:**

Supersedes [Person with cancer—primary site of cancer, code \(ICDO-3\) ANN\(.N\[N\]\)](#)  
[Health](#), Superseded 07/12/2011

Has been superseded by [Person with cancer—primary site of cancer, topography code \(ICD-O-3.1\) ANN.N](#)  
[Health](#), Qualified 03/08/2023

**Implementation in Data Set Specifications:**

[Bowel cancer diagnosed cluster](#)  
[Health](#), Superseded 06/09/2018

[Bowel cancer diagnosed cluster](#)  
[Health](#), Superseded 16/01/2020

[Bowel cancer diagnosed cluster](#)  
[Health](#), Standard 05/02/2021

[Bowel cancer diagnosed cluster](#)  
[Health](#), Superseded 05/02/2021

[Breast cancer \(cancer registries\) NBPDS](#)  
[Health](#), Standard 01/09/2012

[Cancer \(clinical\) DSS](#)  
[Health](#), Superseded 08/05/2014

[Cancer \(clinical\) DSS](#)  
[Health](#), Superseded 14/05/2015

[Cancer \(clinical\) NBPDS](#)  
[Health](#), Standard 14/05/2015

**Implementation in  
Indicators:**

**Used as Numerator**

[Australian Health Performance Framework: PI 3.1.2–Incidence of selected cancers, 2019](#)

[Health](#), Superseded 13/10/2021

[Australian Health Performance Framework: PI 3.1.2–Incidence of selected cancers, 2020](#)

[Health](#), Standard 13/10/2021

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2013](#)

[Health](#), Superseded 30/04/2014

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2014](#)

[Health](#), Superseded 14/01/2015

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2015](#)

[Health](#), Superseded 08/07/2016

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2016](#)

[Health](#), Superseded 31/01/2017

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2017](#)

[Health](#), Superseded 30/01/2018

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2018](#)

[Health](#), Superseded 19/06/2019

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2019](#)

[Health](#), Superseded 13/03/2020

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2020](#)

[Health](#), Standard 13/03/2020

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2021](#)

[Health](#), Standard 16/09/2020

[National Healthcare Agreement: PI 02–Incidence of selected cancers, 2022](#)

[Health](#), Standard 24/09/2021

**Used as Disaggregation**

[Australian Health Performance Framework: PI 2.1.5–Survival of people diagnosed with cancer, 2019](#)

[Health](#), Superseded 01/12/2020

[National Healthcare Agreement: PI 24–Survival of people diagnosed with notifiable cancers, 2019](#)

[Health](#), Superseded 13/03/2020

[National Healthcare Agreement: PI 24–Survival of people diagnosed with notifiable cancers, 2020](#)

[Health](#), Standard 13/03/2020

[National Healthcare Agreement: PI 24–Survival of people diagnosed with notifiable cancers, 2021](#)

[Health](#), Standard 16/09/2020

[National Healthcare Agreement: PI 24–Survival of people diagnosed with notifiable cancers, 2022](#)

[Health](#), Standard 24/09/2021